公开(公告)号：EA010970B1

公开(公告)日：2008-12-30

申请号：EA200400519

申请日：2002-10-10

Applicant: CELLTECH R&D LTD

Inventor： POPPLEWELL ANDREW GEORGE ,  TICKLE SIMON PETER ,  ZINKEWICH-PEOTTI KAREN ,  MORRISON ROBERT KENDALL

IPC: C07K16/28 ,  C12N15/09 ,  A61K39/395 ,  A61K47/48 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  C07K16/46 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/13 ,  C12N15/70 ,  C12P21/02 ,  C12P21/08 ,  G01N33/577

Abstract: Заявленымолекулыантител, содержащиепоменьшеймереодин CDR, полученныйизмышиногомоноклональногоантитела, обладающегоспецифичностьюпоотношениюк KDR человека. Такжезаявлено CDR-привитоеантитело, гдепоменьшеймереодиниз CDR являетсягибридным CDR. Крометого, заявленыпоследовательностиДНК, кодирующиецепимолекулантител, векторы, трансформированныеклетки-хозяеваи применениямолекулантителдлялечениязаболеваний, вкоторыевовлечены VEGF и/или KDR.

公开(公告)号：DE60035687D1

公开(公告)日：2007-09-06

申请号：DE60035687

申请日：2000-04-26

Applicant: CELLTECH R&D LTD

Inventor： BLAGBROUGH IAN ,  GEALL ANDREW JOHN ,  EATON MICHAEL ANTHONY WILLIAM ,  NORMAN TIMOTHY JOHN ,  BAKER TERENCE SEWARD THE MAYES ,  WEIR ANDREW NEIL CHARLES ,  CATTERALL CATHERINE FIONA

IPC: C07C237/22 ,  A61K9/127 ,  A61K47/48 ,  C12N15/88

公开(公告)号：DE602004003256T2

公开(公告)日：2007-05-03

申请号：DE602004003256

申请日：2004-06-18

Applicant: CELLTECH R&D LTD

Inventor： OWEN DAVID ALAN ,  WATSON ROBERT JOHN ,  ALLEN DANIEL REES ,  SHARPE ANDREW ,  DYKE HAZEL JOAN

IPC: C07D211/96 ,  A61K31/451 ,  A61P37/00

公开(公告)号：DE60218436D1

公开(公告)日：2007-04-12

申请号：DE60218436

申请日：2002-01-18

Applicant: CELLTECH R&D LTD

Inventor： BAILEY SLOUGH ,  BROWN JULIEN ALISTAIR ,  BRAND SLOUGH ,  JOHNSON JAMES ANDREW ,  PORTER JOHN ROBERT ,  HEAD JOHN CLIFFORD

IPC: C07D213/81 ,  A61K31/198 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/497 ,  A61P3/10 ,  A61P9/00 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07C229/34 ,  C07C229/36 ,  C07C229/46 ,  C07C233/82 ,  C07C321/22 ,  C07C323/30 ,  C07D213/89 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04

Abstract: Phenylalanine enamide derivatives of formula (1) are described: wherein R 1 , R x , R y , R z , X and V are as defined in claim 1. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.

公开(公告)号：UA78578C2

公开(公告)日：2007-04-10

申请号：UA2005000509

申请日：2003-06-20

Applicant: CELLTECH R&D LTD

Inventor： BROOKINGS DANIEL CHRISTOPHER ,  DAVIS JEREMY MARTIN ,  LANGHEM BARRY JOHN

IPC: A61K31/4743 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/12 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D495/04

Abstract: Bicyclic heteroaromalic derivatives of formula(l)are described: F(l)where: the dashed line joining A and C(Ra) is present and represents a bond and A is a -N= atom or a -C(Rb)= group, or the dashed line is absent and A is a -N(Rb)-, or -C(Rb)(Rc)-1 group; X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O2)- or -NH- group; Y is a nitrogen or substituted carbon atom or 1 a -CH= group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphalic, polyheterocycloaliphalic, aromatic or heleroaromatic group; Ar is an optionally substituted aromatic or heteroaromalic group; and the remaining substituenis are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders. (1)

公开(公告)号：AT348817T

公开(公告)日：2007-01-15

申请号：AT00940569

申请日：2000-06-19

Applicant: CELLTECH R&D LTD

Inventor： BATCHELOR MARK JAMES ,  MOFFAT DAVID FESTUS CHARLES ,  DAVIS JEREMY MARTIN ,  HUTCHINGS MARTIN CLIVE

IPC: A61K31/505 ,  A61K31/506 ,  A61P9/10 ,  A61P9/14 ,  A61P17/06 ,  A61P19/02 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D239/42 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D409/04

Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.

公开(公告)号：AT345328T

公开(公告)日：2006-12-15

申请号：AT04742999

申请日：2004-06-18

Applicant: CELLTECH R&D LTD

Inventor： OWEN DAVID ALAN ,  WATSON ROBERT JOHN ,  ALLEN DANIEL REES ,  SHARPE ANDREW ,  DYKE HAZEL JOAN

IPC: A61P37/00 ,  C07D211/96 ,  A61K31/451

公开(公告)号：ZA200500524B

公开(公告)日：2006-08-30

申请号：ZA200500524

申请日：2005-01-19

Applicant: CELLTECH R&D LTD

Inventor： BROOKINGS DANIEL C ,  DAVIS JEREMY M ,  LANGHAM BARRY J

IPC: A61K20060101 ,  A61K31/4743 ,  A61P20060101 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/12 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D20060101 ,  C07D495/04

Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F(1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N═ atom or a —C(Rb)═ group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH═ group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

公开(公告)号：ES2257561T3

公开(公告)日：2006-08-01

申请号：ES02747621

申请日：2002-08-07

Applicant: CELLTECH R&D LTD

Inventor： DYKE HAZEL JOAN CELLTECH R D L ,  WATSON ROBERT JOHN CELLTECH R

IPC: A61K31/453 ,  A61P1/00 ,  A61P1/02 ,  A61P11/00 ,  A61P11/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P19/10 ,  A61P25/00 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D405/12 ,  C07D309/08 ,  A61K31/445

Abstract: Un compuesto de la fórmula (I): en la que: R1 y R2, que pueden ser iguales o diferentes, son cada uno de ellos, un átomo de hidrógeno o un grupo CF3, CF2H o CFH2, siempre y cuando que cuando R1 o R2, uno de ellos, sea un átomo de hidrógeno, el otro sea un grupo CF3, CF2H o CFH2; y las sales, solvatos o hidratos del mismo.

公开(公告)号：ES2253265T3

公开(公告)日：2006-06-01

申请号：ES00969695

申请日：2000-10-19

Applicant: CELLTECH R&D LTD

Inventor： DAVIS JEREMY MARTIN ,  MOFFAT DAVID FESTUS CHARLES

IPC: A61K31/505 ,  A61P9/00 ,  A61P9/10 ,  A61P9/14 ,  A61P17/06 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D521/00

Abstract: Un compuesto de fórmula (1): en la que R1 es un grupo -XR6 [donde X es un enlace covalente, -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -S(O)-, - S(O2)-, -CH2- o N(R7)- [donde R7 es un átomo de hidrógeno o un grupo alquilo lineal o ramificado] y R6 es un átomo de hidrógeno o halógeno o un grupo alifático, cicloalifático, heteroalifático, heterocicloalifático, aromático o heteroaromático opcionalmente sustituido, o un grupo -NO2, -CN, -SO2N(R8)(R9) [donde R8 y R9, que pueden ser iguales o diferentes, son un átomo de hidrógeno o un grupo alifático, cicloalifático, heteroalifático, heterociciloalifático, aromático o heteroaromático opcionalmente sustituido], - CON(R8)(R9), -CSN(R8)(R9), -NH2 o un grupo amino sustituido; R4 es un grupo X1R11 donde X1 es un enlace covalente o un grupo -C(R12)(R13)- [donde cada uno de R12 y R13 es un átomo de hidrógeno o halógeno o un grupo hidroxilo, alquilo o haloalquilo] o un grupo -C(O)- y R11 es un grupo fenilo, tienilo, tiazolilo o indolilo opcionalmente sustituido; R5 es un átomo de halógeno o un grupo alquinilo; y las sales, solvatos, hidratos y N-óxidos del mismo.